Frequency and characteristics of different clinical phenotypes of chronic obstructive pulmonary disease

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 8, 2015, Pages 992-998

  Miravitlles, M ^a   Barrecheguren, M ^a   Romain Rodriguez M ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HEALTH RESEARCH INSTITUTE OF THE BALEARIC ISLANDS IDISBA   (Spain)

Author keywords

ACOS; COPD; Guidelines; Phenotypes; Treatment

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;

ADULT; AGE DISTRIBUTION; ANXIETY; ARTICLE; CHRONIC BRONCHITIS; CHRONIC COUGH; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEPRESSION; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT; PHENOTYPE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SMOKING; SPAIN; AGED; ASTHMA; BRONCHITIS, CHRONIC; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PSYCHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE;

AGED; ANXIETY; ASTHMA; BRONCHITIS, CHRONIC; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SPAIN; SURVEYS AND QUESTIONNAIRES;

EID: 84937583175     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.15.0021     Document Type: Article

References (35)

1. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012; 379: 1341-1351.
2. Rennard S I, Calverley PMA, Goehring UM, Bredenbröker D, Martinez F J. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subset of patients with COPD. Respir Res 2011; 12: 18.
3. Disantostefano R L, Li H, Rubin D B, Stempel D A. Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open 2013; 3: e001838.
4. Han M K, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med 2014; 189: 1503-1508.
5. Agusti A. The path to personalised medicine in COPD. Thorax 2014; 69: 857-864.
6. Han M K, Agusti A, Calverley P M, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598-604.
7. Miravitlles M, Calle M, Soler-Cataluna J J. Clinical phenotypes of COPD. Identification, definition and implications for guidelines. Arch Bronconeumol 2012; 48: 86-98.
8. Miravitlles M, Soler-Cataluna J J, Calle M, et al. Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol 2014; 50 (Suppl 1): 1-16.
9. Bestall J C, Paul E A, Garrod R, Garnham R, Jones P W, Wedzicha J A. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-586.
10. Soler-Cataluna J J, Martnez-Garć?a M A, Sánchez L, Perpina M, Román P. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med 2009; 103: 692-699.
11. Eisner M D, Trupin L, Katz P P, et al. Development and validation of a survey-based COPD Severity Score. Chest 2005; 127: 1890-1897.
12. Charlson M E, Pompei P, Ales K L, MacKenzie C R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
13. Esteban C, Quintana JM, Aburto M, et al. Impact of changes in physical activity on health-related quality of life among patients with COPD. Eur Respir J 2010; 36: 292-300.
14. Miravitlles M, Cantoni J, Naberan K. Factors associated with low level of physical activity in patients with chronic obstructive pulmonary disease. Lung 2014; 192: 259-265.
15. Badia X, Roset M, Monserrat S, Herdman M, Segura A. La version espanola del EuroQoL: descripcion y aplicaciones. Med Clin 1999; 112: 79-86. [Spanish]
16. Jones P W, Harding G, Berry P, Wiklund I, Chen W H, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J 2009 34: 648-654.
17. Herrero M J, Blanch J, Peri J M, De Pablo J, Pintor L, Bulbena A. A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. Gen Hosp Psychiatry 2003; 25: 277-283.
18. Miravitlles M, Soriano J B, Ancochea J, et al. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. Respir Med 2013; 107: 1053-1060.
19. Hardin M, Silverman E K, Barr R G, et al. The clinical features of overlap between COPD and asthma. Respir Res 2011; 12: 127.
20. Izquierdo-Alonso J L, Rodriguez-Gonzálezmoro JM, de Lucas-Ramos P, et al. Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD). Respir Med 2013; 107: 724-731.
21. Barrecheguren M, Esquinas C, Miravitlles M. The asthma COPD overlap syndrome (ACOS): opportunities and challenges. Curr Opin Pulm Med 2015; 21: 74-79.
22. Soler-Cataluna J J, Cos̈?o B, Izquierdo J L, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 2012; 48: 331-337.
23. Golpe R, Sanjuán Lopez P, Cano Jiménez E, Castro Ańon O, Pérez de Llano L. A distribution of clinical phenotypes in patients with chronic obstructive pulmonary disease caused by biomass and tobacco smoke. Arch Bronconeumol 2014; 50: 318-324.
24. Miravitlles M, Huerta A, Fernández-Villar J A, et al. Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systems. Health Qual Life Outcomes 2014; 12: 120.
25. Seemungal TA R, Donaldson G C, Paul E A, Bestall J C, Jeffries D J, Wedzicha J A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-1422.
26. Donaldson G C, Wilkinson T M A, Hurst J R, Perera W R, Wedzicha J A. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 446-452.
27. Ramon M A, Gimeno-Santos E, Ferrer J, et al. Hospital admissions and exercise capacity decline in patients with COPD. Eur Respir J 2014; 43: 1018-1027.
28. Moy M L, Teylan M, Weston N A, Gagnon D R, Garshick E. Daily step count predicts acute exacerbations in a US cohort with COPD. PLOS ONE 2013: 8; e60400.
29. Hurst J R, Vestbo J, Anzeto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:1128-1138.
30. Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obst Pulm Dis 2014; 9: 889-905.
31. Miravitlles M, Brosa M, Velasco M, Crespo C, Gobartt E, Gonzalez-Rojas N. An economic analysis of pharmacological treatment of COPD in Spain. Respir Med 2009; 103: 714-721.
32. Roche N, Chouaid C, Delclaux B, et al. Multidimensional analyses to assess the relations between treatment choices by physician and patients' characteristics: the example of COPD. BMC Pulm Med 2012; 12: 39.
33. Miravitlles M, Sicras A, Crespo C, et al. Costs of COPD in relation to compliance with guidelines. A study in the primary care setting. Ther Adv Respir Dis 2013; 7: 139-150.
34. Miravitlles M, Soriano J B, Garć?a-Ro F, et al. Prevalence of COPD in Spain: Impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009; 64: 863-868.
35. Miravitlles M, Soler-Cataluna J J, Calle M, Soriano J. Treatment of COPD by clinical phenotypes. Putting old evidence into clinical practice. Eur Respir J 2013; 41: 1252-1256.